Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 5/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587775 | 0.81 | ALOX15 (0.34) | ALOX15AKT2GSK3BHIPK2GRIN2B | |
| SCHEMBL6281359 | 0.77 | AKT2 (0.49) | ALOX15AKT2GSK3BHIPK2KIT | |
| SCHEMBL300491 | 0.74 | ALOX15 (0.41) | ALOX15AKT2HIPK2JAK3F2RL1 | |
| SCHEMBL311710 | 0.72 | BCHE (0.42) | ALOX15AKT2HIPK2JAK3HRH3 | |
| Hydrochloric Acid SCHEMBL9200760 | 0.72 | ALOX15 (0.39) | ALOX15HIPK2HTR2BJAK3F2RL1 | |
| Hydrochloric Acid SCHEMBL29956711 | 0.72 | HIPK2 (0.37) | ALOX15AKT2GSK3BHIPK2JAK3 | |
| SCHEMBL6030119 | 0.72 | KDM4E (0.51) | — | |
| SCHEMBL556899 | 0.71 | LMNA (0.39) | HIPK2F2RL1 | |
| SCHEMBL6403188 | 0.71 | HIPK2 (0.36) | ALOX15AKT2HIPK2JAK3F2RL1 | |
| SCHEMBL3096843 | 0.71 | KDM4E (0.48) | ALOX15HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | ALOX15 778/4885AKT2 3360/4885GSK3B 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.